CIAM
ACRS icon

Caitong International Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Caitong International Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30K Buy
+5,677
New +$25.3K ﹤0.01% 861
2025
Q3 		– Sell
-1,292
Closed -$1.83K – 1886
2025
Q2 		$1.83K Buy
+1,292
New +$1.75K ﹤0.01% 1414

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Caitong International Asset Management's ACRS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 5,677 shares worth $30K. The stake represents ﹤0.01% of the portfolio and ranks #861 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in ACRS as recently as Q2 2025.

Caitong International Asset Management first reported a position in ACRS in Q2 2025 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Caitong International Asset Management held 5,677 shares of Aclaris Therapeutics worth $30K as of Q2 2026.
  • Aclaris Therapeutics was a new Caitong International Asset Management position in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #861 holding.
  • Caitong International Asset Management first reported a position in Aclaris Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.